December 2014 New Products: Company acquires U.S. rights to interstitial cystitis formulation
Company acquires U.S. rights to interstitial cystitis formulation
San Diego—Imprimis Pharmaceuticals, Inc. has entered into a license agreement in which it has acquired the U.S. rights to commercially compound a patented combination of alkalized lidocaine and heparin from Urigen Pharmaceuticals, Inc. The compounded drug formulation has been used to treat patients with interstitial cystitis/painful bladder syndrome. Compounded alkalized lidocaine and heparin instillation procedures have been reimbursable under CPT code 51700. The license is for the U.S. market only and covers certain U.S. patent rights that extend through 2026. Imprimis said it will build a dedicated national education and awareness program called Defeat IC, which the company expects to launch in early 2015.
For more information, visit www.ImprimisPharma.com.
FDA approves prosthesis for women with underactive bladder
Redmond, WA—Vesiflo, Inc. said its direct de novo petition for the inFlow Urinary Prosthesis has been granted by the FDA, allowing the device to be marketed in the United States. The inFlow, a replaceable intraurethral valve pump in a silicone housing, is an alternative to urinary catheters in women with impaired detrusor contractility. The inserted device resides almost entirely in the urethra. To void, the user sits on a toilet, holds a remote control over the lower pelvic area, and presses a button. This magnetically activates the miniature internal pump, which drains the bladder at a normal flow rate.
For more information, visit www.vesiflo.com.
More Urology Products